Filing Flows › Viemed Healthcare (VMD) › Q1 2025
Viemed Healthcare (VMD) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Viemed Healthcare (VMD) reported revenue of $59.1M for the first quarter 2025 (Q1 2025), +17% from a year earlier and -3% from the quarter before. Operating margin was 6.5%, net earnings $2.6M (4.4% of revenue).
Viemed Healthcare, Q1 2025: revenue $59.1M (+17% year over year), operating margin 6.5%, net earnings $2.6M, operating cash flow $2.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59.1M | -3% | +17% |
| Gross profit | $33.3M | -8% | +12% |
| Operating profit | $3.8M | -40% | +74% |
| Net earnings | $2.6M | -39% | +64% |
| Operating cash flow | $2.9M | -81% | +143% |
What changed
Revenue was $59.1M in Q1 2025, up 17% year over year and down 3% from the previous quarter.
Gross margin was 56.3%, down 2.6 points from a year earlier. Operating profit was $3.8M, a 6.5% margin (up 2.1 points year over year). Of the extra revenue versus a year earlier, 19% reached operating profit, above the 4% margin then. Operating expenses grew 7% against revenue growth of 17%. The fastest-growing cost line was SG&A (+15%). Net earnings were $2.6M, up 64% year over year. The effective tax rate was 26.0%.
Operating cash flow was $2.9M (up 143% year over year), 105% of net income including minority interests. Non-cash charges added back $6.6M of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items used $8.8M. Capital expenditures of $15.5M exceeded it, leaving free cash flow of −$12.6M.
Questions
What was Viemed Healthcare's revenue in the first quarter 2025?
Viemed Healthcare (VMD) reported revenue of $59.1M for the first quarter 2025 (Q1 2025), +17% from a year earlier and -3% from the quarter before.
Was Viemed Healthcare profitable in the first quarter 2025?
Operating profit was $3.8M (6.5% of revenue) and net earnings $2.6M.
Source: Viemed Healthcare 10-Q on SEC EDGAR.